Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Trial Profile

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Eszopiclone (Primary) ; Zolpidem (Primary)
  • Indications Depressive disorders; Generalised anxiety disorder; Insomnia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 13 Jan 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Planned initiation date changed from 1 Jan 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top